

31st Annual Prostate Cancer Foundation Scientific Retreat

October 24 - 26, 2024

Omni La Costa Resort Carlsbad, California





GENERAL SESSIONS

Location: Costa Del Sol Ballroom

8:00 AM Registration

Costa Del Sol Foyer

Welcome & Opening Remarks 1:00 PM - 1:05 PM

Howard Soule Prostate Cancer Foundation Andrea Miyahira Prostate Cancer Foundation

Session 1: Tumor Metabolism

1:05 PM - 2:25 PM

Moderator: Andrew Goldstein University of California, Los Angeles

1:05 PM - 1:20 PM	<i>Prostate Lineage-Specific Metabolism Governs Luminal Differentiation</i> <i>and Response to Antiandrogen Treatment</i> Andrew Goldstein University of California, Los Angeles
1:20 PM - 1:25 PM	Discussion
1:25 PM - 1:40 PM	<i>Dietary Target Therapy and Oxidative Death</i> Lloyd Trotman Cold Spring Harbor Laboratory
1:40 PM - 1:45 PM	Discussion
1:45 PM - 2:00 PM	<i>In Vivo Nutrient Tracing and Targeted Metabolic Vulnerabilities in Rare Cancers</i> Heather Christofk University of California, Los Angeles
2:00 PM - 2:05 PM	Discussion

2:05 PM - 2:20 PM *Whole-Food Plant-Based Diet to Control Weight and Metabo-Inflammation in Overweight/Obese Men With Prostate Cancer Receiving ADT* **David Nanus** Weill Cornell Medicine 2:20 PM - 2:25 PM **Discussion**

<u>Session 2: Genomics of Prostate Cancer Racial Disparities</u> 2:25 PM - 3:45 PM

Moderator: Vanessa M. Hayes

The University of Sydney, Australia

2:25 PM - 2:40 PM	African-Ancestry Associated Genomic Differences in Cancer
	Jian Carrot-Zhang
	Memorial Sloan Kettering Cancer Center
2:40 PM - 2:45 PM	Discussion

- 2:45 PM 3:00 PM *The Interplay of Epigenome and Environmental Factors in Prostate Cancer Disparities* Bernard Kwabi-Addo Howard University College of Medicine
- 3:00 PM 3:05 PM **Discussion**
- 3:05 PM 3:20 PM Utilizing a Pan-African Approach to Reduce Prostate Cancer Disparities Clayton Yates John Hopkins School of Medicine
- 3:20 PM 3:25 PM **Discussion**
- 3:25 PM 3:40 PMProstate Cancer Genomic Disparities Across the African Diaspora
Vanessa M. Hayes
The University of Sydney, Australia3:40 PM 3:45 PMDiscussion

<u>Session 3: The Tumor Immune Microenvironment: Reprogramming Macrophages</u> 3:45 PM - 4:45 PM

Moderator: Jelani Zarif

Johns Hopkins University

3:45 PM - 4:00 PM *Metabolic Reprogramming of Tumor-associated Macrophages using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancer Tumors* Jelani Zarif Johns Hopkins University 4:00 PM - 4:05 PM **Discussion**

4:05 PM - 4:20 PM	Investigations in the Tumor Microenvironment Pave the Way for New Cell Therapy Approaches Rosie Kaplan National Cancer Institute
4:20 PM - 4:25 PM	Discussion
4:25 PM - 4:40 PM	<i>Multimodal Pro-Inflammatory Conversion of Tumor Myeloid Stroma</i> <i>by STING Activation</i> Michael Curran
4:40 PM - 4:45 PM	University of Texas MD Anderson Cancer Center Discussion

Session 4: High Impact Clinical Trials for Patients with Prostate Cancer 4:45 PM - 5:45 PM

Moderator: Howard Soule	2
Prostate Cancer Foundation	

4:45 PM - 4:55 PM	Prostate Cancer UK's TRANSFORM Programme: A Randomised Clinical Trial of Prostate Cancer Screening and a National Prostate Cancer Bio- Digital Twin to Power Biomarker Discovery, Innovation and Validation Matthew Hobbs Prostate Cancer UK Rakesh Heer Imperial College London, UK
4:55 PM - 5:00 PM	Discussion
5:00 PM - 5:10 PM	Abiraterone Decanoate (PRL-02/ASP5541): A Precision Approach to Androgen Biosynthesis Inhibition William Moore Astellas
5:10 PM - 5:15 PM	Discussion
5:15 PM - 5:25 PM	<i>Metacure: Multi-Arm Multimodality Therapy for Very High Risk</i> <i>Localized and Low Volume Metastatic Prostatic Adenocarcinoma</i> Howard Scher Memorial Sloan Kettering Cancer Center
5:25 PM - 5:30 PM	Discussion
5:30 PM - 5:40 PM	<i>BMS-986365 (CC-94676), a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer</i> Vivek Arora Bristol Myers Squibb
5:40 PM - 5:45 PM	Discussion

5:45 PM - 5:55 PM Efficacy and Safety of Darolutamide Plus Androgen-Deprivation Therapy (ADT) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) from the Phase 3 ARANOTE Trial Rana McKav University of California, San Diego Discussion 5:55 PM - 6:00 PM 6:00 PM - 6:10 PM A Randomized Multicenter Open-Label Phase III Trial Comparing Enzalutamide vs a Combination of Radium 223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic **mCRPC Andrey Soares** Hospital Albert Einstein, Sao Paulo, Brazil and Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil Discussion 6:10 PM - 6:15 PM

<u>Dinner</u> 6:30 PM - 7:30 PM

Dinner Location: Costa Del Sol Patio

Poster Session and Dessert 7:30 PM - 10:30 PM

Poster Session and Dessert Location: Costa De La Luna Ballroom

6:00 AM - 6:45 AM Breakfast

Location: Costa Del Sol Patio

6:45 AM - 7:00 AM Move to Session

GENERAL SESSIONS Location: Costa Del Sol Ballroom

<u>Session 5: Can AI Drive Innovation in Cancer Research and Cancer Care?</u> 7:00 AM - 8:00 AM

Moderator: Bissan Al-Lazikani The University of Texas MD Anderson Cancer Center

7:00 AM - 7:15 AM	<i>Using AI to Predict Patient Drug Responses and Outcomes from</i> <i>Preclinical Data</i> Katie Campbell Broad and MIT
7:15 AM - 7:20 AM	Discussion
7:20 AM - 7:35 AM	<i>Digital Twins for Drug Development to Individualized Therapy</i> Bissan Al-Lazikani The University of Texas MD Anderson Cancer Center
7:35 AM - 7:40 AM	Discussion
7:40 AM - 7:55 AM	Using Large Language Models to Improve Representation of Patients' Experience with Cancer and its Treatment – Insights from the Lancet Commission on Cancer and Health Systems André Pfob Heidelberg University Hospital
7:55 AM - 8:00 AM	Discussion

SPECIAL LECTURE 8:00 AM - 8:20 AM

Lessons From 20 Years of STAMPEDE

Nicholas James

The Institute of Cancer Research, UK

Introduced by Gerhardt Attard University College London Cancer Institute, UK

8:20 AM - 8:25 AM

Discussion

<u>Session 6: The PCF-VA Partnership: Bringing Precision Medicine to Veterans</u> 8:25 AM - 9:20 AM

Moderator: Isla Garraway

University of California, Los Angeles; Greater Los Angeles VA Healthcare System

8:25 AM - 8:40 AM VA MAPP: Multilevel Data and Biospecimen Repository for Unprecedented Discovery and Validation Isla Garraway University of California, Los Angeles; Greater Los Angeles VA Healthcare System Kara Maxwell University of Pennsylvania; Corporal Michael J. Crescenz VA Medical Center

8:40 AM - 8:55 AM **VA Studies Led by Young Investigators: Landscape of Somatic Prostate Cancer Alterations in the VA population Luca Valle** University of California, Los Angeles; Greater Los Angeles VA Healthcare System

> VA Studies Led by Young Investigators: Treatment and Outcomes of mHSPC in Veterans: Initial use of Tumor Suppressor Genes for Prognosis Martin Schoen Saint Louis University; St. Louis Veterans Affairs Medical Center

8:55 AM - 9:10 AM *Full Spectrum VA Clinical Studies from SOLAR to AI* Nicholas Nickols University of California, Los Angeles; Greater Los Angeles VA Healthcare System **Matthew Rettig** University of California, Los Angeles; Greater Los Angeles VA Healthcare System

9:10 AM - 9:20 AM Session Discussion

<u>SPECIAL ANNOUNCEMENT</u> 9:20 AM -9:25 AM

9:20 AM -9:25 AM

The PCF Gender Equity Networking Initiative

Claire Fletcher Imperial College London, UK

Introduced by Andrea Miyahira Prostate Cancer Foundation

> 9:25 AM - 9:30 AM Discussion

<u>Dr. Felix Feng Special Lecture</u> 9:30 AM - 9:55 AM

Science and Friendship

Himisha Beltran Dana-Farber Cancer Institute

Introduction by Amina Zoubeidi University of British Columbia

9:55 AM - 10:00 AM

Discussion

<u>SPECIAL LECTURE</u> 10:00 AM - 10:30 AM

The JnJ Prostate Cancer Portfolio

John Reed Johnson & Johnson Innovative Medicine

Introduced by Charles Drake Johnson & Johnson Innovative Medicine

10:30 AM - 10:35 AM

Discussion

<u>SPECIAL LECTURE</u> 10:35 AM - 10:55 AM

"We're Not in Kansas Anymore" - Cancer Lessons from the Wizard of Oz

Kenneth Pienta Johns Hopkins University

Introduced by Howard Soule Prostate Cancer Foundation

> 10:55 AM - 11:00 AM Discussion

<u>KEYNOTE ADDRESS</u> 11:00 AM - 12:00 PM

Michael Milken

Founder and Chairman Prostate Cancer Foundation

Introduced by Stuart Holden Prostate Cancer Foundation; University of California, Los Angeles

Group Photo 12:00 PM - 12:10 PM

Location: Costa Del Sol Foyer

Lunch

12:10 PM - 1:00 PM

Location: Costa Del Sol Patio

1:00 PM - 1:15 PM **Move to Session**

Location: Costa Del Sol Ballroom

SPECIAL LECTURE 1:15 PM - 1:30 PM Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer Konrad Stopsack Massachusetts General Hospital; Harvard T.H. Chan School of Public Health Introduced by Philip Kantoff Convergent Therapeutics; Memorial Sloan Kettering Cancer Center; Harvard Medical School; Dana-Farber Cancer Center 1:30 PM - 1:35 PM Discussion

<u>Session 7: Next Generation Theranostics</u> 1:35 PM - 3:00 PM

	Moderator: Michael Hofman Peter MacCallum Cancer Centre, Australia
1:35 PM - 1:40 PM	<i>Introduction</i> Michael Hofman Peter MacCallum Cancer Centre, Australia
1:40 PM - 1:55 PM	PSMA: What's New in 2024? Louise Emmett The University of New South Wales, Australia
1:55 PM - 2:00 PM	Discussion
2:00 PM - 2:15 PM	<i>New Atoms</i> Jason Lewis Memorial Sloan Kettering Cancer Center
2:15 PM - 2:20 PM	Discussion
2:20 PM - 2:35 PM	<i>New Theranostic Targets</i> Andrew Armstrong Duke University
2:35 PM - 2:40 PM	Discussion

2:40 PM -2:55 PM	Trials in Action: What's Hot?
	James Buteau
	Peter MacCallum Cancer Centre, Australia
2:55 PM - 3:00 PM	Discussion

Session 8: Next Generation Cancer Immunotherapies

3:00 PM - 4:20 PM	
	Moderator: Saul Priceman University of Southern California
3:00 PM - 3:15 PM	<i>Novel CAR T Cells for Prostate Cancer</i> Saul Priceman University of Southern California
3:15 PM - 3:20 PM	Discussion
3:20 PM - 3:35 PM	<i>Novel Incorporation of Transgenic Cytokines into Immunotherapeutic</i> <i>Strategies</i> Rosa Nguyen National Cancer Institute
3:35 PM - 3:40 PM	Discussion
3:40 PM - 3:55 PM	<i>Cancer Immunotherapy Using Multiplex Non-Viral Genome</i> <i>Engineered Immune Effector Cells</i> Branden Moriarity University of Minnesota
3:55 PM - 4:00 PM	Discussion
4:00 PM - 4:15 PM	Next Generation CAR T cells for Patients with Cancer Marcela Maus Massachusetts General Hospital
4:15 PM - 4:20 PM	Discussion

<u>Session 9: Advanced Molecular Biology of Lethal Prostate Cancer</u> 4:20 PM - 5:00 PM

Moderator: Adam Sharp Institute of Cancer Research, UK

4:20 PM - 4:35 PMAR-V7 Expression in AR Mutated and Non-Mutated mCRPCAlec Paschalis
Institute of Cancer Research, UK4:35 PM - 4:40 PMDiscussion

4:40 PM - 4:55 PMMinor Intron Splicing in the Pathogenesis of Lethal Prostate Cancer
Mark A. Rubin
University of Bern and Inselspital, Switzerland4:55 PM - 5:00 PMDiscussion

5:00 PM - 7:00 PM Break

Dinner, Awards Ceremony, and Special Lecture 7:00 PM - 10:00 PM

Location: Costa Del Sol Ballroom

PCF Awards Ceremony 7:45 PM - 9:00 PM

2024 PCF Young Investigator Awards

2024 PCF Challenge Awards

2023 PCF Challenge Awards

2024 PCF-Pfizer Visiting Professorship Awards

2024 HBCU-PCF Recognition Award

6:00 AM - 6:45 AM Breakfast

Location: Costa Del Sol Patio

6:45 AM - 7:00 AM Move to Session

GENERAL SESSIONS Location: Costa Del Sol Ballroom

<u>Session 10: Clinical Survivorship 2.0: Metabolic Effects in Survivorship Biology</u> 7:00 AM - 8:05 AM

Moderator: Alicia Morgans

	Dana-Farber Cancer Institute
7:00 AM - 7:05 AM	<i>Introduction</i> Alicia Morgans Dana-Farber Cancer Institute
7:05 AM - 7:20 AM	Metabolism Effects in Response, Resistance, and Complications of Treatment Nima Sharifi University of Miami
7:20 AM - 7:25 AM	Discussion
7:25 AM - 7:40 AM	<i>Exercise and Dietary Impacts on Prostate Cancer Outcomes</i> Stacey Kenfield University of California, San Francisco
7:40 AM - 7:45 AM	Discussion
7:45 AM - 8:00 AM	<i>The Genetic Basis of QOL from CHAARTED</i> Daniel Sentana Dana-Farber Cancer Institute
8:00 AM - 8:05 AM	Discussion

SPECIAL LECTURE 8:05 AM - 8:20 AM

Lessons on the Mechanisms of Plasticity from Small Cell Lung Cancer

Triparna Sen

Icahn School of Medicine at Mount Sinai

Introduced by Andrea Miyahira Prostate Cancer Foundation

8:20 AM - 8:25 AM

Discussion

Session 11: Targeting Post-Transcriptional Gene Regulation in Prostate Cancer 8:25 AM - 9:45 AM Moderator: Duygu Kuzuoglu Ozturk University of California, San Francisco Small Molecule RNA Therapeutics to Target Prostate Cancer 8:25 AM - 8:40 AM Duygu Kuzuoglu Ozturk University of California, San Francisco Discussion 8:40 AM - 8:45 AM 8:45 AM - 9:00 AM The RNA Components of the Translational Machinery in Prostate Cancer Pathogenesis Andrew Hsieh Fred Hutchison Cancer Center 9:00 AM - 9:05 AM Discussion 9:05 AM - 9:20 AM An RNA-Dependent Positive Feedback Loop Drives Malignant Ribosome Biogenesis **Faraz Mardakheh**

University of Oxford, UK

9:20 AM - 9:25 AM Discussion

9:25 AM - 9:40 AM Regulation of Ribosome Biogenesis by Noncoding RNAs in Senescence and Cancer Josh Mendell UT Southwestern 9:40 AM - 9:45 AM Discussion

<u>Session 12: New Biotechnologies in Genomic Medicine</u> 9:45 AM - 10:25 AM Moderator: Howard Soule

Prostate Cancer Foundation

9:45 AM - 10:00 AM Looking Back to Look Forward: Using Genomics and Electronic Health Records to Optimize Current & Future Clinical Decisions Ryon Graf Foundation Medicine

10:00 AM - 10:05 AM **Discussion**

10:05 AM - 10:20 AM *Immune System Profiling - Extracting Dynamic Response Data from the Peripheral Blood* **Michael F. Goldberg** BostonGene 10:20 AM - 10:25 AM **Discussion**

<u>Session 13: Advances in "In Vivo" Cell Therapy Platforms and Novel Small Molecule</u> <u>Cancer Therapies</u> 10:25 AM - 12:05 PM

Moderator: Marco Gottardis Gottardisbiotech LLC

10:25 AM - 10:30 AM *Introduction* Marco Gottardis Gottardisbiotech LLC

10:30 AM - 10:45 AM *Novel Cell Therapy Platforms without Lymphodepletion for Solid Tumors* David Fontana Umoja Biopharma 10:45 AM - 10:50 AM Discussion

10:50 AM - 11:05 AM *In Vivo Cell Engineering with Targeted Lipid Nanoparticles* Priya Karmali Capstan Therapeutics 11:05 AM - 11:10 AM Discussion

11:10 AM - 11:25 AM *Small Molecule Sequence-Selective Translation Inhibitors Inhibit the Growth of MYC-Driven Tumors by Target Deprivation* **Lawrence Hamann** Interdict Bio 11:25 AM - 11:30 AM **Discussion**

11:30 AM - 11:45 AM *Synthetic Lethality in a Plastic Genome - Novel ecDNA Targeted Therapy Platform* **Christian Hassig** Boundless Bio 11:45 AM - 11:50 AM **Discussion**

11:50 AM - 12:00 PM *A Novel NK Cell Activator Phase 1 Trial in Prostate Cancer shows Distinct NK Cell Activity* **Julie Graff** VA Portland Health Care System; Oregon Health & Science University 12:00 PM - 12:05 PM **Discussion**

Closing Remarks

12:05 PM - 12:10 PM Howard Soule Prostate Cancer Foundation Andrea Miyahira Prostate Cancer Foundation

Meeting Adjourned



Program Committee:

Program Committee Co-Chair: Howard Soule (Prostate Cancer Foundation) Program Committee Co-Chair: Andrea Miyahira (Prostate Cancer Foundation)

Bissan Al-Lazikani (The University of Texas MD Anderson Cancer Center)
Isla Garraway (University of California, Los Angeles; Greater Los Angeles VA Healthcare System)
Andrew Goldstein (University of California, Los Angeles)
Marco Gottardis (Gottardisbiotech LLC)
Vanessa M. Hayes (The University of Sydney, Australia)
Michael Hofman (Peter MacCallum Cancer Centre, Australia)
Duygu Kuzuoglu Ozturk (University of California, San Francisco)
Alicia Morgans (Dana-Farber Cancer Institute)
Saul Priceman (University of Southern California)
Davide Ruggero (University of California, San Francisco)
Jelani Zarif (Johns Hopkins University)
Amina Zoubeidi (University of British Columbia)

